August 14, 2013

The study, supported by NJoy and led by independent researchers Mitchell Nides, Ph.D., and Scott Leischow, Ph.D., evaluated nicotine delivery from the NJoy Kings Bold Electronic Delivery System and its short-term potential for smoking reduction or cessation.

August 2, 2013

U.S. Sens. Dick Durbin, D-Ill., and Richard Blumenthal, D-Conn., on Thursday introduced legislation that would retool the labeling requirements for dietary supplement manufacturers, require pre-market certification on new products and require successful efficacy trials.

July 30, 2013

Big data finds another application and another supporter. Sort of.

The full Senate will shortly take up a new track-and-trace bill (S. 959), which would establish a national system for tracking the pedigree and movement of most pharmaceuticals, from point of manufacture and distribution to the dispensing pharmacy and the patient at the end of the supply chain. The goal: to replace the hodge-podge of different state laws with a single, nationwide track-and-trace system capable of capturing the daily flood of drug production, distribution, dispensing and utilization data and channeling it into an accessible tool by which stakeholders and regulators could secure the pharmaceutical supply chain.

July 30, 2013

Hisamitsu America, the manufacturer of Salonpas, an OTC pain patch that is FDA approved and clinically proven, announced the launch of Salonpas Deep Relieving Gel, a topical analgesic solution.

July 16, 2013

The National Community Pharmacists Association CEO Douglas Hoey testified Tuesday before the U.S. House of Representatives Energy and Commerce Subcommittee on Health’s hearing on “Reforming the Drug Compounding Regulatory Framework.”

July 15, 2013

The National Advertising Division referred to the Federal Trade Commission advertising claims made by Fiore RX, for its Antifungal Nail Lacquer after the company failed to respond to an NAD inquiry.

July 8, 2013

Nearly 30 children have been accidentally poisoned by opioid painkiller patches since 1997, according to the Food and Drug Administration, prompting the agency to issue disposal guidelines.

June 25, 2013

Drug makers may be allowed to seek approval for a generic version of an eye drug made by Allergan based on lab tests rather than clinical trials, according to published reports.

May 30, 2013

Syneron Beauty entered the oral care category last year with its Tanda Pearl Ionic Teeth Whitening System and now, Syneron Beauty has created the Pearl brand. Enter Pearl Brilliant White Ionic Teeth Whitening system — the first new, at-home teeth whitening technology to be cleared by the FDA in more than a decade, according to the company.

May 14, 2013

The Food and Drug Administration will review an experimental contraceptive patch made by Actavis, the drug maker said Tuesday.

May 2, 2013

The Justice Department reported it will appeal a recent judicial decision that would require removing any age restriction from the purchase of the Plan B emergency contraceptive, according to a report published in USA Today.

May 2, 2013

A recently released reported that analyzed and measured the level of metals in 32 lip products does not provide any “new meaningful information” and the traces of metals found were not “unexpected given their natural presence in air, soil and water,” according to a statement issued Thursday by the Personal Care Products Council.

April 30, 2013

Syneron Beauty has announced the launch of the Pearl Brilliant White Ionic Teeth Whitening system, which according to the manufacturer, features its patented ionic technology — the first new at-home teeth whitening technology to be cleared by the FDA in more than a decade.

April 29, 2013

A Food and Drug Administration staffer who has led implementation of the Generic Drug User Fee Act has been named to a new director position at the agency, the FDA said Monday.

March 22, 2013

Sens. Bob Casey, D-Pa., and Lisa Murkowski, R-Ark., on Friday introduced the Preventing Abuse of Cough Treatments Act of 2013, which would require retailers to restrict the sale of dextromethorphan-containing products to adults.

March 19, 2013

The Food and Drug Administration has picked Kathleen Uhl to serve as acting director of the Office of Generic Drugs, the agency said.

March 19, 2013

The question of whether a generic drug company can be held liable for harmful side effects from its medicines goes before the Supreme Court Tuesday in a case involving a New Hampshire woman who sustained several injuries after taking a generic pain drug.

March 15, 2013

PharmaSmart International’s comprehensive blood pressure program has recently been validated in two new, independent scientific studies, the company announced today. The company also announced a partnership with Rx-30 Pharmacy System that offers an automated clinical integration of validated PharmaSmart biometrics within the patient record.

March 14, 2013

SoloHealth on Thursday announced it has been selected as one of the Technology Association of Georgia’s Top 10 Innovative Technology Companies. SoloHealth was recognized for its FDA-approved health and wellness kiosk, the SoloHealth Station.

February 28, 2013

Has the explosion in generic utilization curbed pioneer-drug research and development? That's one concern floated by some pharmaceutical industry watchers, who claim that the stunning market share gains made by generic drug makers could reduce incentives for branded drug companies to spend to develop new molecular entities, conduct lengthy clinical trials, gain FDA approval and bring those new drugs to market.

February 14, 2013

Mustela, a European skin care and stretch marks brand, recently introduced three products in a sun care range for babies.

February 14, 2013

Between 2006 and 2010, 1-in-9 sexually experienced women between the ages of 15 and 44 years had used emergency contraception at least once, the National Center for Health Statistics noted in a report released Wednesday.

February 12, 2013

Unexpected toxicities from prescription drugs that emerge years after regulatory approval may be due to poor medication adherence in clinical trials, according to a new study.

February 8, 2013

A new switch paradigm could open the door to $35.7 billion in OTC opportunity, according to a new report recently released by Francesco International.